Law360 (October 20, 2010, 6:32 PM EDT) -- The U.S. Food and Drug Administration on Wednesday recommended new warning labels for certain prostate cancer drugs sold by Pfizer Inc., Bayer AG and others to inform consumers about the potential risk of heart disease and diabetes.
The FDA's Division of Drug Information urged manufacturers to include the warnings on gonadotropin-releasing hormone agonists — a class of drugs mostly used to treat prostate cancer — to alert patients and health care professionals of the drugs' potential side effects.
Patients who took GnRH agonists showed a small increased risk for diabetes, heart attack, stroke and sudden death, the agency said.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!